Xeris Biopharma Holdings, Inc.(XERS)Earnings, Financials & Key Ratios

XERS•NASDAQ

$8.37

2615.6× P/E·Price updated Jul 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Rare Disease Biopharma

AboutXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Show more

Revenue$292M+43.7%
EBITDA$37M+276.3%
Net Income$554K+101.0%
EPS (Diluted)0.00+100.9%
Gross Margin81.7%-0.2%
EBITDA Margin12.7%+222.6%
Operating Margin8.53%+151.5%
Net Margin0.19%+100.7%
ROE4.05%

XERS Price & Volume

Xeris Biopharma Holdings, Inc. (XERS) stock price & volume — 10-year historical chart

Loading chart...

Commercial Scaling Drives Profitability Amidst Debt Constraints

Investment Thesis • Updated 2026Q1

VerdictNeutral

Growth:Accelerating

Profitability:Moderate

Financial:Strained

Cash Flow:Improving

Primary Risk:High debt service burden

Key Thesis Takeaways

Xeris Biopharma has successfully transitioned to operational profitability, evidenced by a 38.3% year-over-year revenue growth in 2026Q1 and the achievement of positive operating income.
While the company's asset-light model and proprietary formulation platform support high gross margins, investors should remain cautious regarding the sustainability of its capital structure given the 2.87 debt-to-equity ratio.
Future performance will likely depend on management's ability to balance aggressive share repurchases, such as the $17M buyback in 2026Q1, against the ongoing requirement to service high-interest debt obligations.

Verdict Logic

while the company has achieved a positive free cash flow margin of 11.5% in 2026Q1, the high debt-to-equity ratio of 2.87 and aggressive $17M share repurchase program suggest significant financial risk remains.

XERS Growth Metrics

Xeris Biopharma Holdings, Inc. (XERS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years70.2%

3 Years38.33%

TTM41.47%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM126.64%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM121.33%

Return on Capital

10 Years-52.33%

5 Years-24.05%

3 Years-7.53%

Last Year10.03%

XERS Recent Earnings

Xeris Biopharma Holdings, Inc. (XERS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 7, 2026

Metric

Actual

Est

EPS

$0.01+465.0%

$0.00

Rev

$82M+3.3%

$80M

Q2 2026

Mar 2, 2026

Metric

Actual

Est

EPS

$0.06+100.0%

$0.03

Rev

$86M+4.4%

$82M

Q4 2025

Nov 6, 2025

Metric

Actual

Est

EPS

$0.00-65.0%

$0.01

Rev

$74M-13.5%

$86M

Q3 2025

Aug 7, 2025

Metric

Actual

Est

EPS

$0.01+66.7%

$0.03

Rev

$72M-1.0%

$72M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 7, 2026	$0.01vs $0.00+465.0%	$82Mvs $80M+3.3%
Q2 2026	Mar 2, 2026	$0.06vs $0.03+100.0%	$86Mvs $82M+4.4%
Q4 2025	Nov 6, 2025	$0.00vs $0.01-65.0%	$74Mvs $86M-13.5%
Q3 2025	Aug 7, 2025	$0.01vs $0.03+66.7%	$72Mvs $72M-1.0%

Based on last 12 quarters of dataView full earnings history →

Latest XERS News

Recent stock market news and headlines for Xeris Biopharma Holdings, Inc. (XERS)

Business Wire·4 days ago

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris' Inducement Equity Plan. Xeris' Inducement Equity Pla.

Business Wire·Jun 30, 2026

Xeris Announces Updates to Its Board of Directors

CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.

Peers Comparison

Key metrics vs top competitors for Xeris Biopharma Holdings, Inc. (XERS)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
XERSXeris Biopharma Holdings, Inc.Current	$8.37	$1.45B	2615.63	43.72%	0.19%	4.05%	—
LNTHLantheus Holdings, Inc.	$102.82	$6.69B	30.15	0.5%	18.05%	24.33%	—
SUPNSupernus Pharmaceuticals, Inc.	$47.41	$2.73B	-69.72	8.63%	-3.74%	-2.73%	—
PAHCPhibro Animal Health Corporation	$34.13	$1.38B	28.68	27.37%	6.35%	29.49%	—
CORTCorcept Therapeutics Incorporated	$91.61	$9.83B	111.72	12.79%	6.23%	7.5%	—
AMRXAmneal Pharmaceuticals, Inc.	$16.92	$5.4B	76.91	8.05%	4.02%	—	—

Compare XERS vs Peers

Xeris Biopharma Holdings, Inc. (XERS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LNTH

Most directly comparable listed peer for XERS.

Scale Benchmark

vs LLY

Larger-name benchmark to compare XERS against a more recognizable public peer.

Peer Set

Compare Top 5

vs LNTH, SUPN, PAHC, CORT

XERS SEC Filings & Documents

Xeris Biopharma Holdings, Inc. (XERS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 7, 2026·SEC

Material company update

Apr 21, 2026·SEC

Material company update

Mar 2, 2026·SEC

10-K Annual Reports

FY 2026

Mar 2, 2026·SEC

FY 2025

Mar 6, 2025·SEC

FY 2024

Mar 6, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when XERS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

XERS Frequently Asked Questions

Xeris Biopharma Holdings, Inc. (XERS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Xeris Biopharma Holdings, Inc.'s revenue?

Xeris Biopharma Holdings, Inc. (XERS) reported $314.9M in revenue for fiscal year 2025. This represents a 29189% increase from $1.1M in 2016.

How fast is Xeris Biopharma Holdings, Inc. growing?

Xeris Biopharma Holdings, Inc. (XERS) grew revenue by 43.7% over the past year. This is strong growth.

Is XERS profitable?

Yes, Xeris Biopharma Holdings, Inc. (XERS) is profitable, generating $12.0M in net income for fiscal year 2025 (0.2% net margin).

Dividend & Returns

What is XERS's return on equity?

Xeris Biopharma Holdings, Inc. (XERS) has a return on equity (ROE) of 4.0%. This is below average, suggesting room for improvement.

What is Xeris Biopharma Holdings, Inc.'s free cash flow?

Xeris Biopharma Holdings, Inc. (XERS) generated $47.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in XERS back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 7, 2026

$0.01vs $0.00+465.0%

$82Mvs $80M+3.3%

Q2 2026

Mar 2, 2026

$0.06vs $0.03+100.0%

$86Mvs $82M+4.4%

Q4 2025

Nov 6, 2025

$0.00vs $0.01-65.0%

$74Mvs $86M-13.5%

Q3 2025

Aug 7, 2025

$0.01vs $0.03+66.7%

$72Mvs $72M-1.0%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

XERSXeris Biopharma Holdings, Inc.Current

$8.37

$1.45B

2615.63

43.72%

0.19%

4.05%

—

LNTHLantheus Holdings, Inc.

$102.82

$6.69B

30.15

0.5%

18.05%

24.33%

—

SUPNSupernus Pharmaceuticals, Inc.

$47.41

$2.73B

-69.72

8.63%

-3.74%

-2.73%

—

PAHCPhibro Animal Health Corporation

$34.13

$1.38B

28.68

27.37%

6.35%

29.49%

—

CORTCorcept Therapeutics Incorporated

$91.61

$9.83B

111.72

12.79%

6.23%

7.5%

—

AMRXAmneal Pharmaceuticals, Inc.

$16.92

$5.4B

76.91

8.05%

4.02%

—